Anaesthesia and myasthenia gravis

[1]  A. Baraka.  Suxamethonium block in the myasthenic patient , 1992, Anaesthesia.

[2]  A. Baraka,et al.  Neuromuscular response to succinylcholine-vecuronium sequence in three myasthenic patients undergoing thymectomy. , 1991, Anesthesia and analgesia.

[3]  J. Eisenkraft,et al.  Response to suxamethonium in a myasthenic patient during remission , 1991, Anaesthesia.

[4]  A. Papatestas,et al.  Sensitivity to vecuronium in myasthenia gravis: a dose-response study , 1990, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[5]  C. Smith,et al.  Cumulative dose-response curves for atracurium in patients with myasthenia gravis , 1989, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[6]  M. Paloheimo,et al.  Halothane‐induced variability in the neuromuscular transmission of patients with myasthenia gravis , 1989, Acta anaesthesiologica Scandinavica.

[7]  I. Wessler,et al.  Control of transmitter release from the motor nerve by presynaptic nicotinic and muscarinic autoreceptors. , 1989, Trends in pharmacological sciences.

[8]  R. Holle,et al.  Recovery of airway protection compared with ventilation in humans after paralysis with curare. , 1989, Anesthesiology.

[9]  Stephen M. Mann,et al.  Resistance to succinylcholine in myasthenia gravis: a dose-response study. , 1988, Anesthesiology.

[10]  K. Mcintosh,et al.  Strategies for the Treatment of Myasthenia Gravis , 1988, Annals of the New York Academy of Sciences.

[11]  W. Erdmann,et al.  PHARMACODYNAMICS OF VECURONIUM BROMIDE IN ANESTHETIZED NEONATES, INFANTS AND CHILDREN , 1988 .

[12]  A. Roses,et al.  Thymectomy as Primary Therapy in Myasthenia Gravis , 1987, Annals of the New York Academy of Sciences.

[13]  L. Rowland.  Therapy in Myasthenia Gravis: Introduction , 1987, Annals of the New York Academy of Sciences.

[14]  D. Grob,et al.  The Course of Myasthenia Gravis and Therapies Affecting Outcome a , 1987, Annals of the New York Academy of Sciences.

[15]  A. Pestronk,et al.  Humoral Pathogenesis of Myasthenia Grayis a , 1987, Annals of the New York Academy of Sciences.

[16]  P. Molenaar,et al.  A Congenital Myasthenic Disorder with Paucity of Secondary Synaptic Clefts: Deficiency and Altered Distribution of Acetylcholine Receptors a , 1987, Annals of the New York Academy of Sciences.

[17]  D. Sanders.  The Electrodiagnosis of Myasthenia Gravis , 1987, Annals of the New York Academy of Sciences.

[18]  S. Berrih-Aknin,et al.  The Role of the Thymus in Myasthenia Gravis: Immunohistological and Immunological Studies in 115 Cases a , 1987, Annals of the New York Academy of Sciences.

[19]  T. Johns.  Long‐Term Corticosteroid Treatment of Myasthenia Gravis , 1987, Annals of the New York Academy of Sciences.

[20]  E. F. Stanley,et al.  Stabilization of Acetylcholine Receptors at Neuromuscular Junctions: Analysis by Specific Antibodies a , 1987, Annals of the New York Academy of Sciences.

[21]  R. Matta,et al.  Clinical Experience in More Than 2000 Patients with Myasthenia Gravis , 1987, Annals of the New York Academy of Sciences.

[22]  G. Matell.  Immunosuppressive Drugs: Azathioprine in the Treatment of Myasthenia Gravis , 1987, Annals of the New York Academy of Sciences.

[23]  A. Papatestas,et al.  Predictors of Respiratory Failure Following Transcervical Thymectomy , 1987 .

[24]  Yong I. Kim.  Lambert‐Eaton Myasthenic Syndrome: Evidence for Calcium Channel Blockade a , 1987, Annals of the New York Academy of Sciences.

[25]  R. Lovelace,et al.  Maximum Thymectomy for Myasthenia Gravis , 1987 .

[26]  G. Noeldge,et al.  Vecuronium for muscle relaxation in patients with myasthenia gravis. , 1986, Anesthesiology.

[27]  T. Henze.  Therapie der Myasthenia gravis , 1986, Deutsche medizinische Wochenschrift.

[28]  J. Hunter,et al.  Vecuronium in the myasthenic patient , 1985, Anaesthesia.

[29]  A. Baraka,et al.  Atracurium in myasthenics undergoing thymectomy. , 1984, Anesthesia and analgesia.

[30]  J. Bach,et al.  Evidence for the presence of immunoreactive acetylcholine receptors on human thymus cells , 1984, Journal of Neuroimmunology.

[31]  A. Baraka,et al.  Undiagnosed myasthenia gravis in a parturient undergoing cesarean section--maternal and neonatal complications. , 1984, Middle East journal of anaesthesiology.

[32]  A. Roses,et al.  Thymectomy in late-onset myasthenia gravis. , 1982, Archives of neurology.

[33]  M. Segawa,et al.  IN VZTRO STUDY OF T‐CELLS REGULATING ANTI‐ACETYLCHOLINE RECEPTOR ANTIBODY FORMATION IN MY ASTHENIA GRAVIS , 1981 .

[34]  Robert G. Miller.  Plasmapheresis in myasthenia gravis , 1981, Annals of neurology.

[35]  A. Baraka,et al.  Effect of neostigmine and pyridostigmine on the plasma cholinesterase activity. , 1981, British journal of anaesthesia.

[36]  W. Bowman.  Prejunctional and Postjunctional Cholinoceptors at the Neuromusclar Junction , 1980, Anesthesia and analgesia.

[37]  R. Hirsh,et al.  Prediction of the Need for Postoperative Mechanical Ventilation in Myasthenia Gravis , 1980, Anesthesiology.

[38]  J. Lindstrom,et al.  Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis. , 1977, The New England journal of medicine.

[39]  A. Baraka.  Suxamethonium-neostigmine interaction in patients with normal or atypical cholinesterase. , 1977, British journal of anaesthesia.

[40]  D. Elmqvist.  Myasthenia Gravis , 1975, The Lancet.

[41]  A. Engel,et al.  Study of long‐term anticholinesterase therapy , 1973, Neurology.

[42]  G. Genkins,et al.  Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients. , 1971, The Mount Sinai journal of medicine, New York.

[43]  D R Waud,et al.  The Relation between Tetanic Fade and Receptor Occlusion in the Presence of Competitive Neuromuscular Block , 1971, Anesthesiology.

[44]  A. Engel,et al.  HISTOMETRIC ANALYSIS OF THE ULTRASTRUCTURE OF THE NEUROMUSCULAR JUNCTION IN MY ASTHENIA GRAVIS AND IN THE MYASTHENIC SYNDROME * , 1971, Annals of the New York Academy of Sciences.

[45]  E. Lambert,et al.  Detailed analysis of neuromuscular transmission in a patient with the myasthenic syndrome sometimes associated with bronchogenic carcinoma. , 1968, Mayo Clinic proceedings.

[46]  W. Paton,et al.  The margin of safety of neuromuscular transmission , 1967, The Journal of physiology.

[47]  A. Baraka,et al.  The Thymus and Myasthenia Gravis , 1966, Middle East journal of anaesthesiology.

[48]  K. Fraser,et al.  The Thymus and Myasthenia Gravis , 1966, Scottish medical journal.

[49]  A. Woolf.  MORPHOLOGY OF THE MYASTHENIC NEUROMUSCULAR JUNCTION * † , 1966, Annals of the New York Academy of Sciences.

[50]  W. W. Hofmann,et al.  An electrophysiological investigation of neuro‐muscular transmission in myasthenia gravis , 1964, The Journal of physiology.

[51]  V. Goldman,et al.  A practice of anaesthesia , 1960, The Journal-lancet.

[52]  H. Churchill-Davidson,et al.  Neuromuscular transmission in myasthenia gravis. , 1955, American Journal of Medicine.

[53]  L. Kadis,et al.  Anesthesia and Uncommon Diseases , 1990 .

[54]  H. Oosterhuis,et al.  Long-term effects of treatment in 374 patients with myasthenia gravis. , 1988, Monographs in allergy.

[55]  H. Müller-Hermelink,et al.  Thymic myoid cells--stimulants and/or targets of autoimmune myasthenia gravis. , 1988, Monographs in allergy.

[56]  V. Dubowitz.  Muscle disorders in childhood. , 1977, Israel journal of medical sciences.

[57]  A. Korczyn.  [Muscle diseases]. , 1974, Harefuah.

[58]  A. Baraka,et al.  Neuromuscular effects of halothane, suxamethonium and tubocurarine in a myasthenic undergoing thymectomy. , 1971, British journal of anaesthesia.